Home Alzheimer’s Disease Trial in Progress: NeoADAURA Will Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC

Trial in Progress: NeoADAURA Will Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC

Neoadjuvant osimertinib (Tagrisso), either as monotherapy or in combination with platinum-based chemotherapy, will be compared against chemotherapy alone in patients with resectable, stage II to IIIB non–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations in the phase 3 NeoADAURA trial (NCT04351555), according to data presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC).1

The primary end point of the study is focused on evaluating major pathological response (MPR), which is defined as less than or equal to 10% of residual cancer cells in the lung tumor specimen following surgery per central assessment. The study sample was based on approximately a 90% power to identify a statistically significant 20 percentage point difference in MPR, with a 2-sided overall significance level of 5% when assuming a 20%…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Recent Comments